Sort   by:  
 Page size 
UnknownExtended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Not available
S-EPMC6317338 | biostudies-literature
UnknownManagement of adverse events associated with idelalisib treatment: expert panel opinion.
Not available
S-EPMC4732460 | biostudies-literature
UnknownUp to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
Not available
S-EPMC9198904 | biostudies-literature
UnknownLong-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Not available
S-EPMC6595265 | biostudies-literature
UnknownThree-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
Not available
S-EPMC4400288 | biostudies-literature
UnknownFinal Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
Not available
S-EPMC10448866 | biostudies-literature
UnknownIbrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
Not available
S-EPMC6908306 | biostudies-literature
UnknownTargeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Not available
S-EPMC3772525 | biostudies-literature
UnknownMeasurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Not available
S-EPMC8718628 | biostudies-literature
UnknownLong-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Not available
S-EPMC9283968 | biostudies-literature
Sort   by:  
 Page size